Indian pharma giant Lupin's shares surged more than 2 per cent to touch the all time high level after the company declared that it had added Huminsulin in India to its diabetes portfolio by purchasing it from Eli Lilly and Co.

Global pharma major Lupin Limited announced today the acquisition of Huminsulin® in India from Eli Lilly and Company to further enhance its diabetes portfolio.

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

Lupin strengthens its diabetes portfolio with the acquisition of Huminsulin products from Eli Lilly, including Insulin Human formulations, widely used for managing type 1 and type 2 diabetes mellitus

Mumbai: Global pharma major Lupin Limited has announced the acquisition of Huminsulin in India from Eli Lilly and Company to further enhance its diabetes portfolio. Lupin has been marketing

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood glucose.

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Global pharma company Lupin announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly), aiming to expand its diabetes care portfolio. Lupin has been marketing the Huminsulin range under existing distribution and promotion agreements with Lilly in India.